Palo Alto, California – March 4, 2013, PREMIER Biosoft, a leading provider of software solutions for life science research, today announced the acquisition of ProteoIQ from NuSep a publicly listed Australia firm. With ProteoIQ, PREMIER Biosoft now offers a broad spectrum of products for mass spectrometry based “Omics” and “Imaging” studies to the research community.
With this acquisition, PREMIER Biosoft enters the attractive proteomics market, after successfully launching best-in-class products for the lipidomics, glycomics and MALDI imaging markets.
ProteoIQ is a software tool for proteomic data analysis that streamlines the process of statistical validation, protein quantification and comparative proteomics on one platform. It supports validation of the proteins identified by other database search tools such as Mascot, SEQUEST, or X!Tandem. ProteoIQ incorporates the False Discovery Rate and Protein Probability approaches for statistical validation of identified proteins. It performs quantitative analysis via spectral counting, precursor intensity, iTRACQ, TMT, SILAC and iCAT workflows. Users can quickly perform differential analysis of results across biological samples thereby facilitating identification of putative biomarkers.
“For the rapidly growing proteomics market, ProteoIQ is a strategic fit to PREMIER Biosoft's existing mass spec product offering and helps consolidate our position as a leader for providing informatics tools for mass spectrometry,” said Arun
Apte, CEO, PREMIER Biosoft.
This is the second acquisition for the company, after completing the acquisition of Redasoft in August 2011.
About PREMIER Biosoft
PREMIER Biosoft (www.premierbiosoft.com) was founded in 1994. The company is led by computer scientists and biologists dedicated to producing cutting-edge intuitive software for research in life sciences. The company's goal is to study the most recent innovations in life sciences and translate them into software products to aid research. Follow PREMIER Biosoft on Twitter @PREMIERBiosoft and on Facebook.
NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on the PrIME technology. This PrIME technology has produced a number of world firsts including the world’s first IVF sperm separation instrument. In short NuSep has redefined the BioSeparations market through innovation and simplification. NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.